Hangzhou Alltest Biotech Co.Ltd(688606) 3 announced on March 28 that the company expects to realize a net profit attributable to the parent company of 1.03 billion yuan to 1.19 billion yuan in the first quarter of 2022, with a year-on-year increase of 585.4% to 691.87%; It is expected to realize the net profit of deducting non parent company from 1.025 billion yuan to 1.185 billion yuan, with a year-on-year increase of 597.74% to 706.7%.
Hangzhou Alltest Biotech Co.Ltd(688606) said that the epidemic situation outside China is still recurring. The company continues to be committed to the prevention and control of covid-19 pneumonia, and covid-19 testing business orders continue to grow steadily, resulting in a significant increase in the company's performance in the first quarter of 2022 compared with the same period of 2021.
